KE Sharquie, AA Noaimi, Glob Dermatol, 2014 - Cited by 6

Psoriasis is a chronic, inflammatory condition that primarily affects the skin, hair, and joints and is associated with significant humanistic and economic consequences. This work induced psoriasis in mice using an imiquimod 5% cream, an immune response modifier that can cause psoriasis-like skin inflammation when given orally. Paquinimod is prepared as an ointment and has been topically given to mice before imiquimod application. In this study, albino mice were allocated into five groups and treated as follows: the control group received only a daily application of cream based on shaved back (62.5mg/2cm) with a daily topical dose of ointment for 14 consecutive days with the oral vehicle. The Imiquimod group received a daily topical

KE Sharquie, MM Al-Waiz, AA Al-Nuaimy, Saudi medical journal, 2005 - Cited by 8

KE Sharquie, WS Al-Dori, IK Sharquie, AA Al–Nuaimy, Hospital, 2004 - Cited by 20

KE Sharquie, AA Noaimi, ER Shwail, J Clin Exp Dermatol Res, 2012 - Cited by 41

KE Sharquie, AA Noaimi, AM Oweid, JSSDDS, 2009 - Cited by 2

HR Al-Hamamy, KE Sharquie, AA Noaimi, WN Hussein, Our Dermatology Online, 2014 - Cited by 6

KE Sharquie, KI Al-Hamdi, AA Noaimi, AA Al-Mohammadi, J Clin Exp Invest www. clinexpinvest. org Vol, 2011 - Cited by 1

Psoriasis is a complex autoimmune disorder characterized by skin inflammation with keratinocyte proliferation, and 85% of cases present as plaque-type psoriasis. Biologics such as ustekinumab (UST) are highly successful therapies for psoriasis. To achieve maximum clinical efficacy while minimizing undesirable effects, therapeutic drug monitoring (TDM) for biologics has emerged. This study aims to measure the UST trough level (TL) and anti-drug antibodies (ADAs) and to evaluate clinical response in Iraqi patients with moderate-to-severe psoriasis in order to make appropriate recommendations for modifying therapy. This cross-sectional study enrolled 75 patients, divided into two groups: Group 1, patients who achieved the UST target TL (≥0.6

KE Sharquie, AA Noaimi, MN Almallah, Journal of Cosmetics, Dermatological Sciences and Applications, 2014 - Cited by 2